Attitudes, Beliefs, and Predictors of Gestational Weight Gain and Postpartum Weight Retention in South Africa: A Mixed Methods Analysis.

Suboptimal gestational weight gain (GWG) is associated with pregnancy complications and postpartum weight retention (PPWR). Little data exists about GWG and PPWR attitudes and beliefs in low-and-middle-income countries (LMICs) to inform interventions. We examined GWG and PPWR attitudes, beliefs, and intentions among pregnant people, with and without HIV, in Cape Town, South Africa.

Trichoderma gets by with a little help from Streptomyces: fungal-bacterial symbiosis in plant growth promotion.

This article comments on: 2024. Local signal from T22 induces host transcriptome and endophytic microbiome leading to growth promotion in sorghum. Journal of Experimental Botany , https://doi.

Microbial community and functional shifts across agricultural and urban landscapes within a Lake Erie watershed.

The role of sediment microbial communities in regulating the loss and retention of nutrients in aquatic ecosystems has been increasingly recognised. However, in the Great Lakes, where nutrient mitigation focuses on harmful algal blooms, there are limited studies examining the fundamental role of water/sediment microbes in nutrient biogeochemical cycling. Little is understood in this regard considering the increase in anthropogenic pressure on in-stream biological processes impacting nutrient flux to lakes.

Duties, tasks, knowledge and skills of an obesity medicine physician: A practice analysis.

Background: Given the evolving nature of obesity medicine, periodic evaluation of its clinical practice is needed to ensure that certification requirements address real-world experience. Practice analysis is a systematic approach to define a field's body of knowledge, and its results can inform the content outline and examination blueprint for a certification examination. This study describes the 2023 practice analysis conducted by the American Board of Obesity Medicine (ABOM).

TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.

At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME before taking part.